Skip to main content

The Globe and Mail

Valeant Pharmaceuticals Intl (VRX-N) Quote

Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 21.98
Day High 22.63
Open:21.98
Price movement based on the high, low and last over the given period.
Previous Close
Volume
Average Volume
Price/Earnings (TTM)
Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant's development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share ttm
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings ttm
Annual Dividend & Yield
Ex-Div Date
Forward P/E
Price/Book
Most Recent Split

Financials

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Quotidian Technical Highlights on Selected Healthcare Stocks -- Quidel, PetMed Express, Valeant Pharma, and Aradigm
PR Newswire - Mon Dec 11, 5:20AM CST
PR Newswire - CMTX
Mon Dec 11, 5:20AM CST
In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on QDEL, PETS, VRX, and ARDM which is a click away at http://www.wallstequities.com/registration. Market Realist reported that the Healthcare sector had a strong performance in November 2017. The Health Care Select Sector SPDR ETF (XLV), which tracks the performance of the Healthcare sector, rose 2.9% in November 2017. On a year-to-date basis, it has returned 22.4% as of December 01st, 2017. Pre-market today, WallStEquities.com shifts focus on the performance of Quidel Corp. (NASDAQ: QDEL), PetMed Express Inc. (NASDAQ: PETS), Valeant Pharmaceuticals International Inc. (NYSE: VRX), and Aradigm Corp. (NASDAQ: ARDM). Wall St. Equities has a wide array of free research reports which include today's stock picks, register now to access them at:
Today's Research Reports on Stocks to Watch: Immunomedics and Valeant Pharmaceuticals
ACCESSWIRE - Thu Dec 7, 7:11AM CST
ACCESSWIRE - CMTX
Thu Dec 7, 7:11AM CST
NEW YORK, NY / ACCESSWIRE / December 7, 2017 / Immunomedics soared yesterday after revealing positive data from a phase 2 study on its lead compound that could treat metastatic triple-negative breast cancer. Shares of Valeant closed down over 5% after a class-action lawsuit will be going to trial against the company. Valeant also received an upgrade this week from Vetr.
Valeant To Participate At The BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
PR Newswire - Thu Dec 7, 7:00AM CST
PR Newswire - CMTX
Thu Dec 7, 7:00AM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Scott A. Hirsch, senior vice president and chief business strategy officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference in New York on Dec. 14, 2017 at 2:00 p.m. EST.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 13.86 +58.59% increase
on 11/15/17
Period Open:14.60
Price movement based on the high, low and last over the given period.
22.15 -0.77% decrease
on 12/12/17
+7.38 (+50.55%) increase
since 11/13/17
3-Month 10.94 +100.91% increase
on 11/02/17
Period Open:14.11
Price movement based on the high, low and last over the given period.
22.15 -0.77% decrease
on 12/12/17
+7.87 (+55.78%) increase
since 09/13/17
52-Week 8.31 +164.50% increase
on 04/24/17
Period Open:14.78
Price movement based on the high, low and last over the given period.
22.15 -0.77% decrease
on 12/12/17
+7.20 (+48.71%) increase
since 12/13/16

All market data is provided by Barchart Solutions (will open in new tab). Copyright © 2017.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

More stories below advertisement